Fortress Biotech, Inc. (FBIO) stock
FBIONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as FBIOP
$1.82+0.11 (+6.43%)
Close on Nov 17, 2026Market cap $66.94MP/E –Yield –
Fortress Biotech revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Fortress Biotech's revenue for the twelve months ending Jun 30, 2026 was $68.47M, up 15.5% year over year. For fiscal 2025 it was $63.26M, up 9.7% from the year before. Over ten years it grew 53.6% a year on average. The highest annual figure on record is $84.51M in fiscal 2023.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $63.26M | +9.7% |
| FY2024 | Dec 31, 2024 | $57.68M | -31.8% |
| FY2023 | Dec 31, 2023 | $84.51M | +11.6% |
| FY2022 | Dec 31, 2022 | $75.74M | +10.1% |
| FY2021 | Dec 31, 2021 | $68.79M | +50.9% |
| FY2020 | Dec 31, 2020 | $45.60M | +24.5% |
| FY2019 | Dec 31, 2019 | $36.63M | +36.3% |
| FY2018 | Dec 31, 2018 | $26.88M | +55.9% |
| FY2017 | Dec 31, 2017 | $17.25M | +4.6% |
| FY2016 | Dec 31, 2016 | $16.48M | +1809.6% |
| FY2015 | Dec 31, 2015 | $863.00K | – |
| FY2014 | Dec 31, 2014 | $0 | – |
| FY2013 | Dec 31, 2013 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $18.72M | +14.0% |
| Q1 FY2026 | Mar 31, 2026 | $16.04M | +22.1% |
| Q4 FY2025 | Dec 31, 2025 | $16.08M | +6.3% |
| Q3 FY2025 | Sep 30, 2025 | $17.63M | +20.5% |
| Q2 FY2025 | Jun 30, 2025 | $16.41M | +10.2% |
| Q1 FY2025 | Mar 31, 2025 | $13.14M | +0.8% |
| Q4 FY2024 | Dec 31, 2024 | $15.12M | -24.2% |
| Q3 FY2024 | Sep 30, 2024 | $14.63M | -57.9% |
| Q2 FY2024 | Jun 30, 2024 | $14.90M | -14.3% |
| Q1 FY2024 | Mar 31, 2024 | $13.03M | +4.8% |
| Q4 FY2023 | Dec 31, 2023 | $19.95M | +21.6% |
| Q3 FY2023 | Sep 30, 2023 | $34.75M | +110.3% |
| Q2 FY2023 | Jun 30, 2023 | $17.39M | -7.9% |
| Q1 FY2023 | Mar 31, 2023 | $12.43M | -48.1% |
| Q4 FY2022 | Dec 31, 2022 | $16.40M | -10.2% |
| Q3 FY2022 | Sep 30, 2022 | $16.53M | -21.6% |
| Q2 FY2022 | Jun 30, 2022 | $18.89M | +5.8% |
| Q1 FY2022 | Mar 31, 2022 | $23.93M | +106.5% |
| Q4 FY2021 | Dec 31, 2021 | $18.28M | +32.9% |
| Q3 FY2021 | Sep 30, 2021 | $21.09M | +122.5% |
| Q2 FY2021 | Jun 30, 2021 | $17.84M | +88.7% |
| Q1 FY2021 | Mar 31, 2021 | $11.59M | -10.3% |
| Q4 FY2020 | Dec 31, 2020 | $13.75M | +23.5% |
| Q3 FY2020 | Sep 30, 2020 | $9.48M | -3.0% |
| Q2 FY2020 | Jun 30, 2020 | $9.46M | +2.2% |
| Q1 FY2020 | Mar 31, 2020 | $12.92M | +99.4% |
| Q4 FY2019 | Dec 31, 2019 | $11.13M | +23.8% |
| Q3 FY2019 | Sep 30, 2019 | $9.77M | +88.9% |
| Q2 FY2019 | Jun 30, 2019 | $9.25M | +35.7% |
| Q1 FY2019 | Mar 31, 2019 | $6.48M | +9.7% |
| Q4 FY2018 | Dec 31, 2018 | $8.99M | +19.2% |
| Q3 FY2018 | Sep 30, 2018 | $5.17M | +105.3% |
| Q2 FY2018 | Jun 30, 2018 | $6.82M | +54.7% |
| Q1 FY2018 | Mar 31, 2018 | $5.90M | +112.5% |
| Q4 FY2017 | Dec 31, 2017 | $7.54M | -47.6% |
| Q3 FY2017 | Sep 30, 2017 | $2.52M | +158.5% |
| Q2 FY2017 | Jun 30, 2017 | $4.40M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.78M | – |
| Q4 FY2016 | Dec 31, 2016 | $14.41M | – |
| Q3 FY2016 | Sep 30, 2016 | $975.00K | – |
See a number that looks wrong?